Impax Asset Management Group’s Pacira BioSciences PCRX Stock Holding History

Impax Asset Management Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19M	Hold	750,027	–	–	0.12%	115
2026 Q1	$17M	Hold	750,027	–	–	0.12%	108
2025 Q4	$19.4M	Buy	750,027 +150,000	+25%	+$3.57M	0.12%	107
2025 Q3	$15.5M	Buy	600,027 +130,000	+28%	+$3.19M	0.09%	116
2025 Q2	$11.2M	Sell	470,027 -70,000	-13%	-$1.76M	0.06%	131
2025 Q1	$13.4M	Hold	540,027	–	–	0.08%	124
2024 Q4	$10.2M	Buy	540,027 +69,424	+15%	+$1.22M	0.05%	159
2024 Q3	$7.08M	Buy	470,603 +210,576	+81%	+$3.6M	0.03%	198
2024 Q2	$7.44M	Hold	260,027	–	–	0.03%	186
2024 Q1	$7.6M	Buy	260,027 +60,000	+30%	+$1.84M	0.03%	196
2023 Q4	$6.75M	Hold	200,027	–	–	0.03%	197
2023 Q3	$6.14M	Hold	200,027	–	–	0.03%	194
2023 Q2	$8.02M	Hold	200,027	–	–	0.03%	179
2023 Q1	$8.16M	Hold	200,027	–	–	0.03%	170
2022 Q4	$7.72M	Sell	200,027 -70,000	-26%	-$3.41M	0.03%	168
2022 Q3	$14.4M	Hold	270,027	–	–	0.07%	131
2022 Q2	$15.7M	Sell	270,027 -15,000	-5%	-$983K	0.08%	128
2022 Q1	$21.8M	Buy	285,027 +26,091	+10%	+$1.74M	0.09%	121
2021 Q4	$15.6M	Buy	258,936 +58,909	+29%	+$3.25M	0.06%	135
2021 Q3	$11.2M	Buy	200,027 +30,000	+18%	+$1.73M	0.05%	147
2021 Q2	$10.3M	Buy	170,027 +45,027	+36%	+$2.85M	0.05%	153
2021 Q1	$8.76M	Buy	+125,000	New	+$8.93M	0.04%	149

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impax Asset Management Group's PCRX Position: Q2 2026 in Review

Impax Asset Management Group held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 750,027 shares worth $19M. The position accounts for 0.12% of the portfolio, ranked #115.

Impax Asset Management Group first reported a position in PCRX in Q1 2021 and has held it in 22 quarters since. The position peaked at $21.8M in Q1 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Impax Asset Management Group held 750,027 shares of Pacira BioSciences worth $19M as of Q2 2026.
Impax Asset Management Group left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up 0.12% of Impax Asset Management Group's portfolio in Q2 2026, its #115 holding.
Impax Asset Management Group first reported a position in Pacira BioSciences in Q1 2021 and has held it in 22 quarters since.
Impax Asset Management Group's Pacira BioSciences position peaked at $21.8M in Q1 2022.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.